研究单位：[1]GeneScience Pharmaceuticals Co., Ltd.[2]Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Wuhan, Hubei, China[3]The First Affiated Hospital of Nanjing Medical University Nanjing, Jiangsu, China[4]Affiliated Hospital of Jiangnan University Wuxi, Jiangsu, China[5]The First Hospital of Jilin University Changchun, Jilin, China[6]The Children's Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang, China[7]Shanghai Children's Hospital of Fudan University Shanghai, China[8]Shanghai Children's Hospital Shanghai, China
研究目的：
This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children with idiopathic short stature (ISS), evaluate its safety and efficacy, and provide scientific and reliable evidence for the medication dosage in Phase III clinical study.
